JCT  Vol.6 No.4 , April 2015
Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer
Abstract: Recent clinical and research development supports the use of 5-fluorouracil in combination with oxaliplatin for the treatment of patients with advanced colorectal cancer (CRC). 5-Fluorouracil (5-FU), which is as an anti-metabolite, is a widely used cytostatic drug. Although the rate of response, quality of life and overall survival differs between CRC patients, the above combination remains a widely used chemotherapeutic regimen. In some cases, a cancer stem cell (CSC) population may resist the majority of chemotherapeutic models. This study investigated if monotherapy is more efficacious than 5-fluorouracil and oxaliplatin combined for the treatment of CRC, using a CRC cell line and a CSC-like line. Cell viability was evaluated by cellular-based assays, and quantitative polymerase chain reaction (q-PCR) assays were performed to assess the expression of specific genes (TYMS, DNMT1, NANOG, DHFR, SHMT1, ERCC1, DPYD) correlated with 5-FU and oxaliplatin resistance. We observed that 5-fluorouracil was more effective in both CRC and CSCs. This finding proved the hypothesis that, in some cases, monotherapy may be more successful in CRC treatment than a drug combination that may be cytotoxic and inflict adverse side effects.
Cite this paper: Toloudi, M. , Apostolou, P. and Papasotiriou, I. (2015) Efficacy of 5-FU or Oxaliplatin Monotherapy over Combination Therapy in Colorectal Cancer. Journal of Cancer Therapy, 6, 345-355. doi: 10.4236/jct.2015.64037.

[1]   Haggar, F.A. and Boushey, R.P. (2009) Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clinics in Colon and Rectal Surgery, 22, 191-197.

[2]   Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H.T., Minsky, B., Nordlinger, B. and Starling, N. (2010) Colorectal Cancer. The Lancet, 375, 1030-1047.

[3]   Wasserberg, N. and Kaufman, H.S. (2007) Palliation of Colorectal Cancer. Surgical Oncology, 16, 299-310.

[4]   Chau, I. and Cunningham, D. (2002) Adjuvant Therapy in Colon Cancer: Current Status and Future Directions. Cancer Treatment Reviews, 28, 223-236.

[5]   de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) Leucovorin and Fluorouracil with or without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology, 18, 2938-2947.

[6]   Shim, B.Y., Lee, K.M., Cho, H.-M., Kim, H.J., Cho, H.J., Yang, J., Kim, J.-G. and Kim, H.-K. (2005) Oxaliplatin/ 5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer. Cancer Research and Treatment, 37, 212-215.

[7]   Dean, M., Fojo, T. and Bates, S. (2005) Tumour Stem Cells and Drug Resistance. Nature Reviews Cancer, 5, 275-284.

[8]   Woodward, W.A., Chen, M.S., Behbod, F., Alfaro, M.P., Buchholz, T.A. and Rosen, J.M. (2007) WNT/Beta-Catenin Mediates Radiation Resistance of Mouse Mammary Progenitor Cells. Proceedings of the National Academy of Sciences of the United States of America, 104, 618-623.

[9]   Liu, G.T., Yuan, X.P., Zeng, Z.H., Tunici, P., Ng, H., Abdulkadir, I.R., Lu, L.Z., Irvin, D., Black, K.L. and Yu, J.S. (2006) Analysis of Gene Expression and Chemoresistance of CD133+ Cancer Stem Cells in Glioblastoma. Molecular Cancer, 5, 67.

[10]   Dean, M. (2009) ABC Transporters, Drug Resistance, and Cancer Stem Cells. Journal of Mammary Gland Biology and Neoplasia, 14, 3-9.

[11]   Liu, Y.B., Peterson, D.A., Kimura, H. and Schubert, D. (1997) Mechanism of Cellular 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Reduction. Journal of Neurochemistry, 69, 581-593.

[12]   Stockert, J.C., Blazquez-Castro, A., Canete, M., Horobin, R.W. and Villanueva, A. (2012) MTT Assay for Cell Viability: Intracellular Localization of the Formazan Product Is in Lipid Droplets. Acta Histochemica, 114, 785-796.

[13]   van Meerloo, J., Kaspers, G.J. and Cloos, J. (2011) Cell Sensitivity Assays: The MTT Assay. Cancer Cell Culture Methods in Molecular Biology, 731, 237-245.

[14]   Sylvester, P.W. (2011) Optimization of the Tetrazolium Dye (MTT) Colorimetric Assay for Cellular Growth and Viability. Drug Design and Discovery Methods in Molecular Biology, 716, 157-168.

[15]   Liu, Y.B. and Nair, M.G. (2010) An Efficient and Economical MTT Assay for Determining the Antioxidant Activity of Plant Natural Product Extracts and Pure Compounds. Journal of Natural Products, 73, 1193-1195.

[16]   Ashraf, H., Taherian, A. and Kerdar, A.N. (2010) Evaluation of Cytotoxicity of Two Root Canal Filling Materials by MTT Assay. Australian Endodontic Journal, 36, 24-28.

[17]   Han, F.X., Lin, H. and Ru, L. (2009) MTT Assay for Detecting 5-Fluorouracil Chemosensitivity of Human Breast Carcinoma Cell Line. Journal of Southern Medical University, 29, 97-99.

[18]   Vichai, V. and Kirtikara, K. (2006) Sulforhodamine B Colorimetric Assay for Cytotoxicity Screening. Nature Protocols, 1, 1112-1116.

[19]   Voigt, W. (2005) Sulforhodamine B Assay and Chemosensitivity. Chemosensitivity Methods in Molecular Medicine, 110, 39-48.

[20]   Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J.T., Bokesch, H., Kenney, S. and Boyd, M.R. (1990) New Colorimetric Cytotoxicity Assay for anticancer-Drug Screening. Journal of the National Cancer Institute, 82, 1107-1112.

[21]   Houghton, P., Fang, R., Techatanawat, I., Steventon, G., Hylands, P.J. and Lee, C.C. (2007) The Sulphorhodamine (SRB) Assay and Other Approaches to Testing Plant Extracts and Derived Compounds for Activities Related to Reputed Anticancer Activity. Methods, 42, 377-387.

[22]   Bonnekoh, B., Wevers, A., Jugert, F., Merk, H. and Mahrle, G. (1989) Colorimetric Growth Assay for Epidermal Cell Cultures by Their Crystal Violet Binding Capacity. Archives of Dermatological Research, 281, 487-490.

[23]   Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y. and Ueno, K. (1996) A Combined Assay of Cell Viability and in Vitro Cytotoxicity with a Highly Water-Soluble Tetrazolium Salt, Neutral Red and Crystal Violet. Biological and Pharmaceutical Bulletin, 19, 1518-1520.

[24]   Grady, J.E., Lummis, W.L. and Smith, C.G. (1960) An Improved Tissue Culture Assay. III. Alternate Methods for Measuring Cell Growth. Cancer Research, 20, 1114-1117.

[25]   Livak, K.J. and Schmittgen, T.D. (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.

[26]   Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J.-I., Yamamura, T. and Hashimoto-Tamaoki, T. (2001) Dual Antitumor Effects of 5-Fluorouracil on the Cell Cycle in Colorectal Carcinoma Cells: A Novel Target Mechanism Concept for Pharmacokinetic Modulating Chemotherapy. Cancer Research, 61, 1029-1037.

[27]   Longley, D.B., Harkin, D.P. and Johnston, P.G. (2003) 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nature Reviews Cancer, 3, 330-338.

[28]   Jensen, S.A., Vainer, B., Witton, C.J., Jorgensen, J.T. and Sorensen, J.B. (2008) Prognostic Significance of Numeric Aberrations of Genes for Thymidylate Synthase, Thymidine Phosphorylase and Dihydrofolate Reductase in Colorectal Cancer. Acta Oncologica, 47, 1054-1061.

[29]   Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Nishi, N., Nihei, Z., Sugihara, K. and Hirayama, R. (2003) Combination of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Gene Expressions in Primary Tumors as Predictive Parameters for the Efficacy of Fluoropyrimidine-Based Chemotherapy for Metastatic Colorectal Cancer. Clinical Cancer Research, 9, 786-791.

[30]   Steck, S.E., Keku, T., Butler, L.M., Galanko, J., Massa, B., Millikan, R.C. and Sandler, R.S. (2008) Polymorphisms in Methionine Synthase, Methionine Synthase Reductase and Serine Hydroxymethyltransferase, Folate and Alcohol Intake, and Colon Cancer Risk. Journal of Nutrigenetics and Nutrigenomics, 1, 196-204.

[31]   DiPaolo, A. and Chu, E. (2004) The Role of Thymidylate Synthase as a Molecular Biomarker. Clinical Cancer Research, 10, 411-412.

[32]   Apostolou, P., Toloudi, M., Chatziioannou, M., and Papasotiriou, I. (2011) Predictive Value of Molecular-Cellular Methodologies for Response to Chemotherapy with CisPlatin/5Fu in Colon Tumours. Journal for Clinical Studies, 3, 28-32.

[33]   Salonga, D., Danenberg, K.D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D.D., Lenz, H.J., Leichman, C.G., Leichman, L., Diasio, R.B., et al. (2000) Colorectal Tumors Responding to 5-Fluorouracil Have Low Gene Expression Levels of Dihydropyrimidine Dehydrogenase, Thymidylate Synthase, and Thymidine Phosphorylase. Clinical Cancer Research, 6, 1322-1327.

[34]   Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F.L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J.J., et al. (2007) Gene Expression of ERCC1 As a novel prognostic marker in Advanced Bladder Cancer Patients Receiving Cisplatin-Based Chemotherapy. Annals of Oncology, 18, 522-528.

[35]   Yu, Y.J., Kanwar, S.S., Patel, B.B., Nautiyal, J., Sarkar, F.H. and Majumdar, A.P. (2009) Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Translational Oncology, 2, 321-328.

[36]   Patel, B.B., Sengupta, R., Qazi, S., Vachhani, H., Yu, Y., Rishi, A.K. and Majumdar, A.P. (2008) Curcumin Enhances the Effects of 5-Fluorouracil and Oxaliplatin in Mediating Growth Inhibition of Colon Cancer Cells by Modulating EGFR and IGF-1R. International Journal of Cancer, 122, 267-273.